{"id":15303,"date":"2023-08-10T22:48:00","date_gmt":"2023-08-10T14:48:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15303"},"modified":"2024-11-27T22:51:33","modified_gmt":"2024-11-27T14:51:33","slug":"regeneron-pharmaceuticals-acquires-decibel-therapeutics-for-hearing-loss-gene-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15303","title":{"rendered":"Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies"},"content":{"rendered":"\n

US-based biopharmaceutical company Regeneron Pharmaceuticals Inc., (NASDAQ: REGN<\/a>) has announced the acquisition of fellow US firm Decibel Therapeutics Inc., (NASDAQ: DBTX), a partner since 2017 specializing in gene therapies for hearing loss. Regeneron is paying an initial USD 4 per Decibel share, valuing the transaction at approximately USD 109 million, with the potential for the value to rise to USD 213 million upon the achievement of certain development and regulatory milestones.<\/p>\n\n\n\n

History of Collaboration and Focus on Hearing Loss Therapies<\/strong>
Decibel and Regeneron first formed a collaboration in 2017, which was extended in 2021, to focus on the development of three gene therapies targeting different forms of congenital, monogenic hearing loss. The lead candidate in their pipeline is DB-OTO, which is currently under investigation in the global Phase I\/II CHORDTM study.<\/p>\n\n\n\n

DB-OTO and Preclinical Programs<\/strong>
DB-OTO is an investigational cell-selective adeno-associated virus (AAV) gene therapy designed to provide durable, physiological hearing to individuals with profound, congenital hearing loss caused by mutations of the otoferlin gene. Decibel’s preclinical programs also include AAV.103 for people with GJB2-related hearing loss and AAV.104 for people with stereocilin (STRC)-related hearing loss, showcasing the company’s commitment to addressing various genetic causes of hearing impairment.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US-based biopharmaceutical company Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has announced the acquisition of fellow US…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2170,66,2412,1166,1426],"class_list":["post-15303","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-decibel-therapeutics","tag-gene-therapy","tag-nasdaq-dbtx","tag-nasdaq-regn","tag-regeneron-pharmaceuticals"],"yoast_head":"\nRegeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US-based biopharmaceutical company Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has announced the acquisition of fellow US firm Decibel Therapeutics Inc., (NASDAQ: DBTX), a partner since 2017 specializing in gene therapies for hearing loss. Regeneron is paying an initial USD 4 per Decibel share, valuing the transaction at approximately USD 109 million, with the potential for the value to rise to USD 213 million upon the achievement of certain development and regulatory milestones.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15303\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15303\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-10T14:48:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-27T14:51:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15303#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15303\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies\",\"datePublished\":\"2023-08-10T14:48:00+00:00\",\"dateModified\":\"2024-11-27T14:51:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15303\"},\"wordCount\":211,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Decibel Therapeutics\",\"Gene therapy\",\"NASDAQ: DBTX\",\"NASDAQ: REGN\",\"Regeneron Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15303#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15303\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15303\",\"name\":\"Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-10T14:48:00+00:00\",\"dateModified\":\"2024-11-27T14:51:33+00:00\",\"description\":\"US-based biopharmaceutical company Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has announced the acquisition of fellow US firm Decibel Therapeutics Inc., (NASDAQ: DBTX), a partner since 2017 specializing in gene therapies for hearing loss. Regeneron is paying an initial USD 4 per Decibel share, valuing the transaction at approximately USD 109 million, with the potential for the value to rise to USD 213 million upon the achievement of certain development and regulatory milestones.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15303#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15303\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15303#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies - Insight, China's Pharmaceutical Industry","description":"US-based biopharmaceutical company Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has announced the acquisition of fellow US firm Decibel Therapeutics Inc., (NASDAQ: DBTX), a partner since 2017 specializing in gene therapies for hearing loss. Regeneron is paying an initial USD 4 per Decibel share, valuing the transaction at approximately USD 109 million, with the potential for the value to rise to USD 213 million upon the achievement of certain development and regulatory milestones.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15303","og_locale":"en_US","og_type":"article","og_title":"Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15303","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-10T14:48:00+00:00","article_modified_time":"2024-11-27T14:51:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15303#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15303"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies","datePublished":"2023-08-10T14:48:00+00:00","dateModified":"2024-11-27T14:51:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15303"},"wordCount":211,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Decibel Therapeutics","Gene therapy","NASDAQ: DBTX","NASDAQ: REGN","Regeneron Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15303#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15303","url":"https:\/\/flcube.com\/?p=15303","name":"Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-10T14:48:00+00:00","dateModified":"2024-11-27T14:51:33+00:00","description":"US-based biopharmaceutical company Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has announced the acquisition of fellow US firm Decibel Therapeutics Inc., (NASDAQ: DBTX), a partner since 2017 specializing in gene therapies for hearing loss. Regeneron is paying an initial USD 4 per Decibel share, valuing the transaction at approximately USD 109 million, with the potential for the value to rise to USD 213 million upon the achievement of certain development and regulatory milestones.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15303#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15303"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15303#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Regeneron Pharmaceuticals Acquires Decibel Therapeutics for Hearing Loss Gene Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15303","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15303"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15303\/revisions"}],"predecessor-version":[{"id":15304,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15303\/revisions\/15304"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15303"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15303"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15303"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}